Skip to main content
Premium Trial:

Request an Annual Quote

NgeneBio Partners With MGI Tech on Precision Cancer Diagnostics

NEW YORK – South Korean next-generation sequencing-based diagnostic firm NGeneBio said on Friday that it has entered a collaboration agreement with Chinese sequencing platform company MGI Tech to expand the commercial access of NGeneBio's cancer testing products.

Financial details of the deal were not disclosed.

As part of the partnership, Seoul-based NGeneBio said it will combine its NGS-based precision cancer diagnostic tests with MGI’s DNBSeq-G99 sequencer. The two companies will also "strengthen their competitiveness in the precision medical field" through joint marketing and global distribution collaboration, it said.

"Through cooperation with MGI, which has an extensive distribution network, NGeneBio expects to expand its overseas market in earnest by packaging NGS sequencing equipment with NGeneBio's diagnostic reagents and analysis software," NGeneBio said in a statement.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.